Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Abstract

These findings demonstrate that UB-VV100 generates functional CAR T cells in vivo, which could expand patient access to CAR T technology in both hematological and solid tumors without the need for ex vivo cell manufacturing.